PIK3CA-TP53 co-mutation as a biomarker of overall survival in malignant tumor.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15001-e15001
Author(s):  
Hongyan Wang ◽  
Xiaopeng Zhao ◽  
Xu He ◽  
Miao Wang ◽  
Haoran Zhang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Double Mutant ◽  
Malignant Tumors ◽  
Single Gene ◽  
Hazard Ratio ◽  
Cancer Type ◽  
Cancer Types

e15001 Background: Overall survival (OS) is an important endpoint, with the advantage that there is minimal ambiguity in defining an OS event; the patient is either alive or dead. Some single gene mutations, such as TP53, were identified as important predictors of shorter OS in malignant tumors. However, the relationship between gene co-mutation and OS of malignant tumors is poorly defined. Methods: Genomic and OS data were derived from The Cancer Genome Atlas (TCGA) databases. We defined the double-mutant gene pair as “hit pair” in the specific cancer type if statistically significant OS difference was observed in at least one of three comparison (double-mutant samples vs gene A-only-mutant samples; double-mutant samples vs gene B-only-mutant samples; gene A-only-mutant samples vs gene B-only-mutant samples). Results: PIK3CA-TP53 co-mutation was evaluated as “hit pair” in seven cancer types: GBM (Glioblastoma multiforme), HNSC (Head and neck squamous cell carcinoma), LUSC (Lung squamous cell carcinoma), SARC (Sarcoma), SKCM (Skin cutaneous melanoma), UCEC (Uterine corpus endometrial carcinoma), and UCS (Uterine carcinosarcoma). In SARC and SKCM, the expected hazard ratio was higher in both-mutant group than TP53-only-mutant group, and neither genes were correlated with OS. Especially in SKCM, after we took “neither” group (both genes were wild-type) into comparison, hazard ratio of both-mutant group was significantly higher than neither group. Single-gene mutation didn’t make difference on hazard ratio, which indicated that the both-mutant interaction made the leading contribution. In GBM, LUSC, and UCS, the significant difference of hazard ratio between TP53-only-mutant group and PIK3CA-only-mutant group was neutralized in the both-mutant group, to some extent equivalent to “average effect (OS curve of double-mutant group was between that of only single gene mutant groups)". For PIK3CA-TP53 in HNSC, both-mutant group and TP53-only-mutant group carried with a higher hazard ratio than PIK3CA-only-mutant group. It suggested that the increasing hazard ratio in both-mutant group might be resulted from TP53 mutation. For the circumstance in UCEC, TP53 and PIK3CA were testified to be correlated with higher and lower hazard ratio, respectively and both-mutant group and TP53-only-mutant group both with significantly higher hazard ratio than PIK3CA-only-mutant group, which further verified the greater strength of TP53 than PIK3CA in both-mutant group. Conclusions: In summary, our study identified PIK3CA-TP53 co-mutation as a predictor of OS in seven cancer types: GBM, HNSC, LUSC, SARC, SKCM, UCEC, and UCS, especially in SARC and SKCM.

scholarly journals Integrated Analysis of MicroRNA (miRNA) and mRNA Profiles Reveals Reduced Correlation between MicroRNA and Target Gene in Cancer

2018 ◽  
Vol 2018 ◽  
pp. 1-15 ◽  
Author(s):  
Xingsong Li ◽  
Xiaokang Yu ◽  
Yuting He ◽  
Yuhuan Meng ◽  
Jinsheng Liang ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Mirna Target ◽  
Target Gene ◽  
Target Genes ◽  
Integrated Analysis ◽  
Cancer Type ◽  
Gene Pairs ◽  
Cancer Types

Background. Accumulating evidences demonstrated that microRNA-target gene pairs were closely related to tumorigenesis and development. However, the correlation between miRNA and target gene was insufficiently understood, especially its changes between tumor and normal tissues. Objectives. The aim of this study was to evaluate the changes of correlation of miRNAs-target pairs between normal and tumor. Materials and Methods. 5680 mRNA and 5740 miRNA expression profiles of 11 major human cancers were downloaded from the Cancer Genome Atlas (TCGA). The 11 cancer types were bladder urothelial carcinoma, breast invasive carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma, lung squamous cell carcinoma, stomach adenocarcinoma, and thyroid carcinoma. For each cancer type, we firstly obtained differentially expressed miRNAs (DEMs) and genes (DEGs) in tumor and then acquired critical miRNA-target gene pairs by combining DEMs, DEGs and two experimentally validated miRNA-target interaction databases, miRTarBase and miRecords. We collected samples with both miRNA and mRNA expression values and performed a correlation analysis by Pearson method for miRNA-target pairs in normal and tumor, respectively. Results. We totally got 4743 critical miRNA-target pairs across 11 cancer types, and 4572 of them showed weaker correlation in tumor than in normal. The average correlation coefficients of miRNA-target pairs were different greatly between normal (-0.38 ~ -0.61) and tumor (-0.04 ~ -0.26) for 11 cancer type. The pan-cancer network, which consisted of 108 edges connecting 35 miRNAs and 89 target genes, showed the interactions of pairs appeared in multicancers. Conclusions. This comprehensive analysis revealed that correlation between miRNAs and target genes was greatly reduced in tumor and these critical pairs we got were involved in cellular adhesion, proliferation, and migration. Our research could provide opportunities for investigating cancer molecular regulatory mechanism and seeking therapeutic targets.

Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study

2005 ◽  
Vol 23 (34) ◽  
pp. 8646-8654 ◽  
Author(s):  
Barbara Burtness ◽  
Meredith A. Goldwasser ◽  
William Flood ◽  
Bassam Mattar ◽  
Arlene A. Forastiere
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Response Rate ◽  
Hazard Ratio ◽  
Phase Iii ◽  
End Points ◽  
Metastatic Squamous Cell Carcinoma

Purpose Therapy of recurrent/metastatic squamous cell carcinoma of the head and neck results in median progression-free survival (PFS) of 2 months. These cancers are rich in epidermal growth factor receptor (EGFR). We wished to determine whether the addition of cetuximab, which inhibits activation of EGFR, would improve PFS. Patients and Methods Patients with recurrent/metastatic squamous cell carcinoma of the head and neck were randomly assigned to receive cisplatin every 4 weeks, with weekly cetuximab (arm A) or placebo (arm B). Tumor tissue was assayed for EGFR expression by immunohistochemistry. The primary end point was PFS. Secondary end points of interest were response rate, toxicity, overall survival, and correlation of EGFR with clinical end points. Results There were 117 analyzable patients enrolled. Median PFS was 2.7 months for arm B and 4.2 months for arm A. The hazard ratio for progression of arm A to arm B was 0.78 (95% CI, 0.54 to 1.12). Median overall survival was 8.0 months for arm B and 9.2 months for arm A (P = .21). The hazard ratio for survival by skin toxicity in cetuximab-treated patients was 0.42 (95% CI, 0.21 to 0.86). Objective response rate was 26% for arm A and 10% for arm B (P = .03). Enhancement of response was greater for patients with EGFR staining present in less than 80% of cells. Conclusion Addition of cetuximab to cisplatin significantly improves response rate. There was a survival advantage for the development of rash. Progression-free and overall survival were not significantly improved by the addition of cetuximab in this study.

scholarly journals Real-world Treatment Patterns and Outcomes with Systemic Therapies in Unresectable Locally Advanced and Metastatic Cutaneous Squamous Cell Carcinoma in Germany

2021 ◽  
Author(s):  
Felix Kramb ◽  
Christoph Doerfer ◽  
Andreas Meiwes ◽  
Karthik Ramakrishnan ◽  
Thomas Eigentler ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Systemic Treatment ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Hazard Ratio ◽  
Free Survival

Advanced cutaneous squamous cell carcinoma is a challenge to treat. Conventional systemic treatment options include chemotherapy and epidermal growth factor receptor-inhibitors. The aim of this study was to assess clinical outcomes with systemic treatments in advanced cutaneous squamous cell carcinoma. Patients receiving systemic treatment at the Tübingen Dermato-Oncology centre between 2007 and 2017 were identified (n = 59). Median age was 76 years (interquartile range (IQR) 71–80 years), 83.1% of patients were male, 72.9% had metastatic cutaneous squamous cell carcinoma, and 27.1% had unresectable locally advanced cutaneous squamous cell carcinoma. During median follow-up of 52 weeks (IQR 27–97 weeks), overall response rate was 14.3%, and disease control rate was 53.6%. Median progression-free survival was 15 weeks (IQR 8–42 weeks), and median overall survival was 52 weeks (IQR 27–97 weeks). Patients receiving chemoradiation vs chemo­therapy alone showed better overall survival (hazard ratio 0.41, p = 0.014,) and progression-free survival (hazard ratio 0.42, p = 0.009); no differences were observed for metastatic cutaneous squamous cell carcinoma vs locally advanced cutaneous squamous cell carcinoma patients. Although chemotherapy and/or cetuximab showed limited outcomes in advanced cutaneous squamous cell carcinoma, such therapy may still be an option when anti-PD-1 treatment is contraindicated.

scholarly journals Proposal of a prognostically relevant grading scheme for pulmonary squamous cell carcinoma

2015 ◽  
Vol 47 (3) ◽  
pp. 938-946 ◽  
Author(s):  
Wilko Weichert ◽  
Claudia Kossakowski ◽  
Alexander Harms ◽  
Peter Schirmacher ◽  
Thomas Muley ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Tumour Cell ◽  
Morphological Characteristics ◽  
Hazard Ratio ◽  
Nuclear Size ◽  
Nest Size ◽  
Prognostic Impact

Recent studies in lung adenocarcinoma established a clinically relevant histomorphology-based classification. In contrast, no morphological classifiers have yet been implemented into routine diagnostics for lung squamous cell carcinoma (SQCC). However, morphology-based characteristics putatively impacting on survival have been proposed.We analysed a cohort of 541 SQCC patients with complete clinical follow-up data for morphological characteristics (keratinisation, tumour cell budding, size of tumour cell nests, nuclear size and stromal content). Morphological characteristics were correlated with clinical data and patient outcome.Keratinisation, budding, stromal content and tumour cell nest size, but not nuclear size, were associated with distinct clinicopathological characteristics and survival. SQCC patients with keratinisation, small cell nest size, high stromal content and extensive budding had shorter overall survival. A combined grading scheme composed of the two most reliable validated prognostic markers,i.e.budding and nest size, resulted in an age-, stage- and sex-independent prognosticator for overall survival with a hazard ratio of 1.6 for grade 2 tumours and a hazard ratio of 3.7 for grade 3 tumours when compared with grade 1 neoplasms (p<0.001).Morphological characteristics of SQCC have significant prognostic impact and could constitute the basis for a diagnostically relevant future SQCC grading scheme.

scholarly journals Inflammatory markers as prognostic factors of recurrence in advanced stage squamous cell carcinoma of the head and neck

2020 ◽  
Vol 27 (3) ◽  
Author(s):  
M. Valdes ◽  
J. Villeda ◽  
H. Mithoowani ◽  
T. Pitre ◽  
M. Chasen
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Inflammatory Markers ◽  
Hazard Ratio ◽  
Advanced Stage ◽  
Risk Of Relapse

BACKGROUND. Multiple immunologic parameters have provided useful prognostic and assessment significance in different cancers, including head and neck squamous cell carcinoma. We sought to identify whether pre-treatment inflammatory markers could prognosticate recurrence in patients with advanced (stage III or IV) head and neck squamous cell carcinomas that underwent therapy with curative intent in a tertiary care center between January 2010 and December 2012.METHODS. We registered patient demographics, primary tumor characteristics, Human papillomavirus (HPV) status, pre-therapeutic inflammatory markers including body mass index (BMI), neutrophil-to-lymphocyte ratio (NLR), C-reactive protein (CRP), and serum albumin; therapy received, date of relapse, death or last follow up. The main outcome was relapse free survival (RFS). Overall survival (OS) was a secondary outcome.RESULTS. 235 charts were reviewed, 118 were included. Of these, 86 were oropharyngeal (50 HPV related, 18 were non-HPV related, 17 not available) and 32 non-oropharyngeal (19 HPV related, 7 non-HPV related, and 6 not available). Median follow-up was 2.45 years (IQR, 1.65-3.3). With regards to RFS, HPV positive status had an adjusted HR of 0.357 (95% CI 0.173-0.776, p=0.0087) and for NLR >=5, the raw HR was 1.637 (95% CI 0.673-3.983, p=0.2771). For OS, the raw HR for NLR >=5 was 2.997 (95% CI 1.280-7.018-, p=0.0114), and for HPV positive status, the raw HR was 0.514 (95% CI 0.226-1.169, p=0.1125). Only 54 patients had CRP available for analysis. For RFS, CRP >=8 had a raw HR of 2.350 (95% CI 1.1062-5.198, p=0.0349) and a raw HR of 1.455 (95% CI 0.497-4.260, p=0.4940) for OS. When adjusting NLR for age, gender and p16 positive status, NLR had a decreased hazard ratio of 2.352 (95% CI= 0.945-5.853, p=0.0659) for overall survival.CONCLUSIONS. NLR>=5 at presentation is not associated with a higher risk of relapse but is associated with a higher risk of death in patients with squamous cell carcinoma of the head and neck. CRP >=8 was associated with a higher risk of relapse but not death. Lastly, HPV positive status was protective with a lower risk of relapse but not death. Interestingly, we found that when adjusting NLR for age, gender and HPV positive status, NLR had a decreased hazard ratio and therefore potentially protective status for overall survival.

scholarly journals A systematic analysis of immune genes and overall survival in cancer patients

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Qian Wang ◽  
Pan Li ◽  
Weidong Wu
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Immune System ◽  
Cell Carcinoma ◽  
Signaling Pathway ◽  
Squamous Cell ◽  
Lower Grade ◽  
Tcr Signaling ◽  
Immune Genes ◽  
Cancer Types

Abstract Background Overall survival (OS) is a key endpoint measure in the management of patients with cancer. Immunotherapy has become a dominant strategy in cancer therapy. To investigate the relationship between OS and the immune system, we assessed the role of immune genes in OS in 8648 patients across 22 cancer types. Methods Gene expression data and clinical information were collected from The Cancer Genome Atlas (TCGA) and cBioPortal. Survival analysis was performed with a Cox proportional hazards regression model. Results (1) The number of prognostic genes, prognostic immune genes (PIGs) and the hazard ratio (HR) of PIGs in different cancer types all varied greatly; (2) KEGG pathway enrichment analyses indicated that the prognostic genes of 6 cancer types were significantly enriched in multiple (≥5) immune system-related pathways. Of the PIGs in these 6 cancer types, we screened 48 common PIGs in at least 5 cancer types. Eleven out of the 48 PIGs were found to participate in the T cell receptor (TCR) signaling pathway according to the STRING database. Among these genes, ZAP70, CD3E, CD3G, CD3D, and CD247 were part of the TCR ‘signal-triggering module’; (3) High expression of the PIGs involved in the TCR signaling pathway was associated with improved OS in 5 cancer types (breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), head and neck squamous cell carcinoma (HNSC), lung adenocarcinoma (LUAD), and sarcoma (SARC)), but was associated with decreased OS in brain lower-grade glioma (LGG). Conclusions The TCR signaling pathway played a distinct role in the OS of these 6 cancer types.

scholarly journals Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial

2018 ◽  
Vol 36 (27) ◽  
pp. 2796-2803 ◽  
Author(s):  
Hong Yang ◽  
Hui Liu ◽  
Yuping Chen ◽  
Chengchu Zhu ◽  
Wentao Fang ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Neoadjuvant Chemoradiotherapy ◽  
Hazard Ratio ◽  
Phase Iii ◽  
Carcinoma Of The Esophagus

Purpose The efficacy of neoadjuvant chemoradiotherapy (NCRT) plus surgery for locally advanced esophageal squamous cell carcinoma (ESCC) remains controversial. In this trial, we compared the survival and safety of NCRT plus surgery with surgery alone in patients with locally advanced ESCC. Patients and Methods From June 2007 to December 2014, 451 patients with potentially resectable thoracic ESCC, clinically staged as T1-4N1M0/T4N0M0, were randomly allocated to NCRT plus surgery (group CRT; n = 224) and surgery alone (group S; n = 227). In group CRT, patients received vinorelbine 25 mg/m2 intravenously (IV) on days 1 and 8 and cisplatin 75 mg/m2 IV day 1, or 25 mg/m2 IV on days 1 to 4 every 3 weeks for two cycles, with a total concurrent radiation dose of 40.0 Gy administered in 20 fractions of 2.0 Gy on 5 days per week. In both groups, patients underwent McKeown or Ivor Lewis esophagectomy. The primary end point was overall survival. Results The pathologic complete response rate was 43.2% in group CRT. Compared with group S, group CRT had a higher R0 resection rate (98.4% v 91.2%; P = .002), a better median overall survival (100.1 months v 66.5 months; hazard ratio, 0.71; 95% CI, 0.53 to 0.96; P = .025), and a prolonged disease-free survival (100.1 months v 41.7 months; hazard ratio, 0.58; 95% CI, 0.43 to 0.78; P < .001). Leukopenia (48.9%) and neutropenia (45.7%) were the most common grade 3 or 4 adverse events during chemoradiotherapy. Incidences of postoperative complications were similar between groups, with the exception of arrhythmia (group CRT: 13% v group S: 4.0%; P = .001). Peritreatment mortality was 2.2% in group CRT versus 0.4% in group S ( P = .212). Conclusion This trial shows that NCRT plus surgery improves survival over surgery alone among patients with locally advanced ESCC, with acceptable and manageable adverse events.

193 Differences in thyroid immune-related adverse events between lung cancer types, a retrospective analysis

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A208-A208
Author(s):  
Rahim Jiwani ◽  
Heather Brody ◽  
Yuxuan Mao ◽  
Elisabeth Lee ◽  
Rita Rehana ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Thyroid Dysfunction ◽  
Cohort Analysis ◽  
Cancer Type ◽  
Chi Square ◽  
Cancer Types

BackgroundImmune modulation of the PD-1/PD-L1 pathway is a promising treatment of various malignancies however, alteration of the pathway is known to cause many immune related adverse events (irAEs) including thyroid dysfunction. Whether the frequency of thyroid irAEs differ between lung cancer types has not yet been studied.MethodsA total of three hundred twenty-nine lung cancer patients treated with immunotherapy at East Carolina University between April 2014 and July 2019 were included in a retrospective cohort analysis. Baseline TSH and TSH at each treatment cycle were recorded along with the type of lung cancer, specific agent used, timing of thyroid dysfunction and need for levothyroxine replacement. The frequency of thyroid irAEs as defined by TSH < 0.4 or > 4.0 and its relationship with lung cancer types were analyzed using chi square tests and logistic regression.ResultsOf the three hundred twenty-nine patients; 54.4% had adenocarcinoma, 31.6% had squamous cell carcinoma, 11.3% had small cell carcinoma and 2.7% had poorly differentiated lung cancer. Overall, 135 patients (41.0%) developed thyroid irAEs (table 1). Pearson’s chi square test was used to compare the frequencies of thyroid irAEs for each type of lung cancer against all other lung cancer types. Patients with squamous cell carcinoma developed significantly less thyroid irAEs (32.7%), compared to all other lung cancers (44.9%), X2 (1, N = 329) = 4.4, p = 0.037. Conversely, patients with lung cancer types other than squamous cell carcinoma were more likely to develop thyroid irAEs, OR = 1.68 (95% CI: 1.03 – 2.73).ConclusionsThyroid irAEs occurred significantly less frequently in patients with squamous cell carcinoma than those with other lung cancer types. This analysis may allow clinicians to better identify patients more likely to develop irAE thyroid dysfunction based on lung cancer type.Abstract 193 Table 1Frequency of lung cancer type and thyroid dysfunction within each group

scholarly journals Development and validation of an individualized immune prognostic model in stage I–III lung squamous cell carcinoma

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Qi-Fan Yang ◽  
Di Wu ◽  
Jian Wang ◽  
Li Ba ◽  
Chen Tian ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Prognostic Model ◽  
Lung Squamous Cell Carcinoma ◽  
Risk Groups ◽  
Stage I ◽  
Tissue Samples ◽  
Mutation Burden

AbstractLung squamous cell carcinoma (LUSC) possesses a poor prognosis even for stages I–III resected patients. Reliable prognostic biomarkers that can stratify and predict clinical outcomes for stage I–III resected LUSC patients are urgently needed. Based on gene expression of LUSC tissue samples from five public datasets, consisting of 687 cases, we developed an immune-related prognostic model (IPM) according to immune genes from ImmPort database. Then, we comprehensively analyzed the immune microenvironment and mutation burden that are significantly associated with this model. According to the IPM, patients were stratified into high- and low-risk groups with markedly distinct survival benefits. We found that patients with high immune risk possessed a higher proportion of immunosuppressive cells such as macrophages M0, and presented higher expression of CD47, CD73, SIRPA, and TIM-3. Moreover, When further stratified based on the tumor mutation burden (TMB) and risk score, patients with high TMB and low immune risk had a remarkable prolonged overall survival compared to patients with low TMB and high immune risk. Finally, a nomogram combing the IPM with clinical factors was established to provide a more precise evaluation of prognosis. The proposed immune relevant model is a promising biomarker for predicting overall survival in stage I–III LUSC. Thus, it may shed light on identifying patient subset at high risk of adverse prognosis from an immunological perspective.

Proton beam radiotherapy of locally advanced or recurrent conjunctival squamous cell carcinoma: experience of the CATANA Centre

2020 ◽  
pp. 1-8
Author(s):  
Roberto Milazzotto ◽  
Rocco Luca Emanuele Liardo ◽  
Giuseppe Privitera ◽  
Luigi Raffaele ◽  
Vincenzo Salamone ◽  
...  
Keyword(s):  
Overall Survival ◽  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Proton Beam ◽  
Squamous Cell ◽  
Locally Advanced ◽  
Disease Free Survival ◽  
Proton Beam Radiotherapy ◽  
Conjunctival Squamous Cell Carcinoma ◽  
The Impact

Abstract Aim: Conjunctival squamous cell carcinoma (SCC) is a rare tumour of the ocular region and microscopic radical surgical is difficult. There are no single guidelines for therapeutic management and the role of radiation therapy is not clearly defined although conventionally photon or electron beams are used. Proton beam radiotherapy (PBRT) is a new option for a conservative approach and allows good sparing of the organs at risk. Materials and methods: After surgical resection, we collected 15 cases treated at our institution with PBRT. The dose delivered was between 48 and 60 Gy relative biological effectiveness (RBE), with fractions of 12–15 Gy RBE. Results: After an average period of 48 months, the patients achieved excellent disease control (overall survival and disease-free survival: 86·6%), with minimal acute and late toxicity. Findings: In this work, we present our experience on the use of PBRT technique in SCC treatment. A larger sample of patients is needed to draw conclusions about the impact of this treatment on disease recurrence and overall survival.

Sign in / Sign up

Export Citation Format

Share Document